Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells

Yue Wu1, Ke Zu, Mary Ann Warren

  • 1Department of Cancer Chemoprevention, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Insights

Selenium inhibits cancer cell survival by reducing Akt phosphorylation. It affects both the PI3K pathway and calcineurin-mediated dephosphorylation, offering new therapeutic strategies for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is crucial for cancer cell survival and is frequently dysregulated.
  • Selenium's ability to suppress phospho-Akt is known, but its precise mechanism on Akt phosphorylation and dephosphorylation remains unclear.

Purpose of the Study:

  • To investigate how selenium affects Akt phosphorylation and dephosphorylation in PC-3 prostate cancer cells.
  • To determine if selenium primarily targets the PI3K-PDK1 axis or phosphatase-mediated dephosphorylation of Akt.

Main Methods:

  • Utilized PC-3 prostate cancer cells, which are phosphatase and tensin homologue-null.
  • Assessed Akt phosphorylation at Thr308 and Ser473 sites.
  • Measured PI3K activity and protein levels of PI3K and phospho-PDK1.
  • Examined membrane localization of PDK1 and Akt via Western blotting.
  • Investigated the role of calcineurin using calcium chelators and specific inhibitors.

Main Results:

  • Selenium reduced Akt phosphorylation at both Thr308 and Ser473, with Thr308 being more sensitive.
  • PI3K activity decreased by 30% in selenium-treated cells, reducing membrane recruitment of PDK1 and Akt.
  • Selenium significantly diminished membrane localization of PDK1 and Akt.
  • The inhibitory effect of selenium on phospho-Akt(Ser473) was reduced by calcineurin inhibition, suggesting a role for this phosphatase.

Conclusions:

  • Selenium inhibits Akt phosphorylation through both reduced PI3K activity and enhanced calcineurin-mediated dephosphorylation.
  • These findings reveal a dual mechanism for selenium's anti-cancer effects, targeting key cell survival pathways.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...